September 2, 2026

Rigel to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September:

- **Citi's 2026 Biopharma Back to School Conference in New York, NY**
  Rigel will participate in one-on-one meetings on Wednesday, September 9.

- **Cantor Global Healthcare Conference 2026 in New York, NY**
  Rigel will participate in one-on-one meetings and present a company overview on Thursday, September 10, at 11:30 a.m. ET.

- **H.C. Wainwright 28th Annual Global Investment Conference in New York, NY**
  Rigel will participate in one-on-one meetings and present a company overview on Tuesday, September 15, at 10:00 a.m. ET.

To access the live webcasts or archived recordings of the Cantor and H.C. Wainwright conference presentations, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com

Media:

David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-participate-in-upcoming-september-investor-conferences-302866936.html

SOURCE Rigel Pharmaceuticals, Inc.